Loading clinical trials...
Loading clinical trials...
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)
Conditions
Interventions
Balstilimab
Zalifrelimab
Locations
7
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Arizona Oncology Associates
Tucson, Arizona, United States
Hoag Gynecologic Oncology
Newport Beach, California, United States
University of California, San Francisco Medical Center
San Francisco, California, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
Last Updated
April 30, 2025
NCT05468034
NCT04541381
NCT06043817
NCT07446322
NCT03137095
NCT06340568
Lead Sponsor
Agenus Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions